Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ROMIDEPSIN
- Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
- Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
- Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
- A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
- Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
- Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
- A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
- Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
- Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
- Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
- Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
- Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
- Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
- LRAs United as a Novel Anti-HIV Strategy.
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
- Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
- Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
- Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
- Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation
- Romidepsin Plus 3BNC117 Phase 2a Study
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
- Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
- A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
- Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
- Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
- A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
- Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
- Long-term Use of Romidepsin in Patients With CTCL
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
- Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
- Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
- Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
- Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
- Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
- Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
- Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
- Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
- A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma
- Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
- Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
- Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
- An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
- Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
- Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
- A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
- Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
- Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
- A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
- Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
- A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
- Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
- Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
- Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial of Romidepsin and Bortezomib for Multiple Myeloma
- A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
- A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
- FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
- Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
- A Research Study for Patients With Metastatic Renal Cell Carcinoma
- A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
- A Research Study for Patients With Prostate Cancer
- Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
- Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
- FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
- FR901228 in Treating Patients With Metastatic Breast Cancer
- Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
- Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
- FR901228 in Treating Patients With Recurrent High-Grade Gliomas
- Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
- FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
- FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
- Depsipeptide to Treat Thyroid and Other Advanced Cancers
- FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
- FR901228 in Treating Patients With Hematologic Cancer
- Depsipeptide in Treating Patients With Solid Tumors
- Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Clinical trials list
click for details